Researchers have found two different compounds that can block malaria transmission when added to pre-existing treatment regimes. Credit: turkletom

VLPM01 is a pre-erythrocytic vaccine designed to deliver the circumsporozoite (CSP) antigen on the company’s inserted alphavirus virus-like particle (i-αVLP) vaccine platform.

To be conducted at the Walter Reed Army Institute of Research (WRAIR) in Maryland, the Phase I/IIa trial will evaluate the safety, immunogenicity and efficacy of the vaccine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will start enrolling volunteers this month.

It will use mosquito-bite induced controlled human malaria infection (CHMI) with Plasmodium falciparum parasite, which causes the disease in humans.

Participants, after receiving the vaccines, will be exposed to disease-causing parasites through mosquito bites under controlled laboratory settings.

In case the trial participants get infected, antimalarial drugs are used for their treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CHMI is performed in malaria-naive adults to study the protective efficacy of vaccines. The approach is said to act as a precursor for field studies in malaria-endemic regions.

VLP Therapeutics CEO Wataru Akahata said: “This clinical trial represents an important milestone for VLP Therapeutics as we initiate our first clinical trial and is a great accomplishment for the team at VLP Therapeutics.

“This represents the culmination of several years of work by our team and our partners and we are grateful for the support we have received from our partners, including the US Department of Defense.”

Statistics show that malaria is responsible for nearly 200 million illness cases and more than 400,000 deaths each year.